Kairos Gmbh

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry dedicated to delivering actionable insights.

Scientists who are now working to combat major widespread diseases more effectively need a newly defined infrastructural environment and newly designed technical equipment as well. Only with the proper up-to-date tools will their research results stay on the forefront of progress. The establishment of the six German Centers for Health Research (DZG) created the interdisciplinary and inter-institutional basis for Translational Medicine. The aim of these centers is that patients will benefit more quickly from medical therapies and products in the future.

The active, constant and barrier-free exchange of information between medical treatment and research is the first prerequisite for research results from laboratories to reach medical care more quickly, or at all in the future.

The concept “from bench to bed” supports the need for this translation of research to treatment. To do this new, specialized system IT are essential.

KAIROS an IQVIA business is an IT specialist who draws on more than ten years of experience in developing IT system solutions for the healthcare sector. In addition to specialist technological knowledge in the implementation of medical middleware platforms, we have extensive know-how in the IT-supported orchestration of work processes via workflow engines. That not only sounds good, but also reflects the claim and reality of KAIROS. Started as a classic "start-up", the size and market shares quickly corresponded more to a "grown-up company".